Aerovate Therapeutics Q1 2024 Earnings Report

Aerovate Therapeutics EPS Results

• Actual EPS: -$29.05
• Consensus EPS: -$25.90
• Beat/Miss: Missed by -$3.15
• One Year Ago EPS: N/A

Aerovate Therapeutics Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Aerovate Therapeutics Announcement Details

• Quarter: Q1 2024
• Date: 5/13/2024
• Time: N/A
• Conference Call Date: Monday, May 13, 2024
• Conference Call Time: 7:00AM ET

Aerovate Therapeutics (NASDAQ:AVTE) is a clinical-stage biopharmaceutical company focused on developing inhaled therapies for patients with debilitating pulmonary diseases. By leveraging a proprietary aerosol delivery platform, the company aims to deliver potent small-molecule anti-fibrotic and anti-inflammatory agents directly to the lungs, thereby maximizing local drug exposure while minimizing systemic side effects.

The company’s lead product candidate is an inhaled formulation of an established anti-fibrotic agent currently in early-phase clinical trials for the treatment of idiopathic pulmonary fibrosis (IPF). In addition to its IPF program, Aerovate is advancing preclinical molecules designed to target other chronic lung conditions, including scleroderma-related interstitial lung disease and chronic obstructive pulmonary disease. Each program is engineered to exploit the company’s aerosol technology, which is designed to enhance pulmonary deposition and improve patient tolerability compared with oral therapies.

Founded in 2020 and headquartered in the United States, Aerovate Therapeutics has assembled a team of experienced drug developers and clinicians to shepherd its pipeline through clinical development. The company collaborates with leading research institutions and regulatory authorities to support trial design and anticipate broader geographic expansion, positioning Aerovate to address significant unmet needs in fibrotic and inflammatory lung diseases worldwide.